Nonlipid primary and secondary prevention strategies for coronary heart disease.
Widespread application of proven primary and secondary preventive strategies for coronary heart disease would result in substantial savings of life and health care dollars. Proven strategies (excluding lipid therapy) include quitting smoking, treating hypertension, physical activity, aspirin therapy, and appropriate use of anticoagulants, beta blockers, and angiotensin-converting enzyme inhibitors in survivors of myocardial infarction. Estrogen replacement therapy is currently under clinical investigation. Avoidance of obesity and tight control of diabetes are prudent interventions as yet unproved by clinical trials. Unfortunately, preventive strategies are frequently underutilized. The greatest challenge for preventive cardiology is to put into practice what we already know to prevent the development and progression of atherosclerosis.
Maron
D J
DJ
Division of Cardiology, Vanderbilt University School of Medicine, Nashville, TN 37232-6300, USA.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001786:Blood Glucose; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003327:Coronary Disease / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D015914:Estrogen Replacement Therapy; D015444:Exercise; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D006973:Hypertension / Q000628:therapy; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011322:Primary Prevention / Q000191:economics / Q000379:methods*; D016540:Smoking Cessation; D015431:Weight Loss
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D010975:Platelet Aggregation Inhibitors